GlassScriptPhysician profile
Sandra M Macsweeney
NPI 1841474715
$2,274.04
in general payments reported to CMS, 2019-2025
21 companies · $1,753 in 2025
The $1,753 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.58 · 2024: $499 · 2025: $1,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $880.65 | 2024-2025 | Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $223.68 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $217.59 | 2022-2025 | Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $146.23 | 2025 | Amvuttra |
| Noven Pharmaceuticals, INC. | $122.50 | 2024 | Xelstrym |
| Sanofi-Aventis U.S. LLC | $105.53 | 2024-2025 | |
| Lilly USA, LLC | $85.70 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Xeris Pharmaceuticals, INC. | $81.34 | 2025 | Recorlev |
| Abbvie INC. | $46.35 | 2024-2025 | |
| Pfizer INC. | $45.21 | 2025 | |
| Glaxosmithkline, LLC. | $43.16 | 2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $40.66 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $40.03 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.15 | 2024 | Jardiance |
| Amgen INC. | $31.87 | 2025 | Evenity, Repatha, Otezla |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $30.10 | 2025 | Voquezna |
| Exact Sciences Corporation | $23.60 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $22.23 | 2025 | Cuvitru |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.99 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $16.52 | 2025 | Capvaxive |
| Medtronic, INC. | $14.95 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Macsweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.